Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines
- Wednesday, November 20, 2019, 6:59
- Environment
- Add a comment
CAMBRIDGE, Mass., Nov. 20, 2019 /PRNewswire/ — Werewolf Therapeutics, an oncology biotherapeutics company advancing a pipeline of next generation, transformative cancer treatments, today announced the completion of its $56 million Series A financing. The company is developing novel…
About the Author
adminasapcorp has written 41834 stories on this site.